Stockscreener 앱 받기
14.14
2.82%
-0.41
시간 외 거래:
14.14
전일 마감가:
$14.55
열려 있는:
$14.28
하루 거래량:
122.74K
Relative Volume:
0.39
시가총액:
$888.64M
수익:
-
순이익/손실:
$-168.02M
주가수익비율:
-3.1341
EPS:
-4.5116
순현금흐름:
$-152.10M
1주 성능:
-3.61%
1개월 성능:
+3.74%
6개월 성능:
-36.51%
1년 성능:
+41.40%
1일 변동 폭
$13.98
$14.36
1주일 범위
$13.98
$15.10
52주 변동 폭
$8.70
$26.18
Dbv Technologies Adr Stock (DBVT) Company Profile
명칭
Dbv Technologies Adr
전화
33(0)155427878
주소
107 AVENUE DE LA REPUBLIQUE, CHATILLON
Compare DBVT vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DBVT
Dbv Technologies Adr
|
14.14 | 894.92M | 0 | -168.02M | -152.10M | -4.5116 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Dbv Technologies Adr Stock (DBVT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-12-03 | 개시 | Guggenheim | Buy |
| 2025-05-29 | 재개 | Goldman | Sell |
| 2023-01-04 | 업그레이드 | Societe Generale | Hold → Buy |
| 2022-12-16 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-05-10 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-09-14 | 업그레이드 | Societe Generale | Hold → Buy |
| 2021-01-22 | 다운그레이드 | Societe Generale | Hold → Sell |
| 2020-11-02 | 업그레이드 | Societe Generale | Sell → Hold |
| 2020-08-06 | 다운그레이드 | Societe Generale | Buy → Sell |
| 2020-08-05 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-17 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-01-09 | 업그레이드 | Stifel | Hold → Buy |
| 2019-12-16 | 개시 | Citigroup | Buy |
| 2019-09-05 | 재개 | Morgan Stanley | Equal-Weight |
| 2019-06-17 | 개시 | Goldman | Buy |
| 2018-12-20 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2018-12-20 | 다운그레이드 | BofA/Merrill | Buy → Underperform |
| 2018-12-20 | 다운그레이드 | Jefferies | Buy → Hold |
| 2018-12-20 | 다운그레이드 | Stifel | Buy → Hold |
| 2017-10-31 | 업그레이드 | Societe Generale | Sell → Hold |
| 2017-10-24 | 다운그레이드 | Societe Generale | Buy → Sell |
| 2017-10-23 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2017-06-23 | 개시 | Deutsche Bank | Buy |
| 2017-03-16 | 업그레이드 | Societe Generale | Hold → Buy |
| 2016-09-26 | 개시 | JMP Securities | Mkt Outperform |
| 2015-12-03 | 개시 | Barclays | Overweight |
| 2015-10-23 | 개시 | BofA/Merrill | Buy |
모두보기
Dbv Technologies Adr 주식(DBVT)의 최신 뉴스
DBV Technologies (NASDAQ:DBVT) Shares Up 6.2%Here's Why - MarketBeat
European ADRs Started The Week Slightly Higher In US Trading - Finimize
MPM BioImpact LLC discloses 6.2% stake in DBV Technologies (DBVT) - Stock Titan
DBV technologies S.A. (ADR) (DBV1.SG) balance sheet - Yahoo Finance UK
DBV Technologies (NASDAQ:DBVT) Stock Price Up 8.4%Time to Buy? - MarketBeat
RA Capital discloses DBV Technologies (DBVT) 5.8% ownership via ADS holding - Stock Titan
DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq - The Manila Times
DBV Technologies Announces Sale of Approximately $50 - GlobeNewswire
Form S-3ASR DBV TECHNOLOGIES S.A. For: 27 July By Investing.com - Investing.com Canada
Spyre Therapeutics (SYRE) Receives a Buy from Guggenheim - The Globe and Mail
Europe’s US-Listed ADRs Edged Higher Late Friday Morning - Finimize
DBV Technologies: Viaskin's FDA Path Still Leaves Room For More Upside (NASDAQ:DBVT) - Seeking Alpha
DBV Technologies on Track for Lowest Close Since December 2025 -- Data Talk - Moomoo
DBV Technologies stock falls on $150M share offering plan - Investing.com
DBV Technologies Files At-The-Market (ATM) Prospectus for Up to $150 Million of Sales - The Manila Times
symbol__ Stock Quote Price and Forecast - CNN
DBV Technologies Plans Viaskin Peanut Launch Prep, If Approved - Stock Titan
DBV Technologies Reports Second Quarter and Half-Year 2026 Financial Results and Business Update - markets.businessinsider.com
DBV Technologies narrows Q2 loss, funds operations into Q3 2027 - scanx.trade
DBV Technologies Announces the Filing of its 2026 Half-Year Report ― Conditions for Accessing or Consulting the Report - markets.businessinsider.com
DBV Technologies (NASDAQ: DBVT) sees $174.9M cash and Q3 2027 runway - Stock Titan
DBV Technologies Announces the Filing of its 2026 Half-Year - GlobeNewswire
DBV Technologies to Report Second Quarter 2026 Financial Results and Business Update on July 16, 2026 - markets.businessinsider.com
DBV Technologies' July 16 webcast will cover Q2 results - Stock Titan
ETFs Investing in DBV Technologies SA Sponsored ADR Stocks - TradingView
Europe’s US-Listed ADRs Slipped Late Tuesday Morning - Finimize
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF - markets.businessinsider.com
DBV Technologies S.A. - Via Ritzau
DBV Technologies posts half-year liquidity contract figures - Stock Titan
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
DBV Technologies (NASDAQ: DBVT) targets Q3 2026 for VIASKIN Peanut BLA filing - Stock Titan
DBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review Process in Preparation for Filing - The Manila Times
European ADRs Rose As Biopharma Names Led The Pack - Finimize
A40WEX Forecast — Price Target — Prediction for 2027 - TradingView
European ADRs Climb In Thursday U.S. Morning Session: ARGX, PHIA, CRTO In Focus - foreignpolicyjournal.com
European ADRs Rose In US Trading Late Thursday Morning - Finimize
DBV1 Forecast — Price Target — Prediction for 2027 - TradingView
DBV Technologies Announces Inclusion in the Euronext Tech Leaders Index - markets.businessinsider.com
DBV Technologies (ENXTPA:DBV) Advances Peanut Patch With New Phase 3 Data And Infant Trial - Yahoo Finance
DBV Technologies (DBVT) soars 5.3%: Is further upside left in the stock? - MSN
DBV Technologies (DBVT) Soars 5.3%: Is Further Upside Left in the Stock? - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Enliven Therapeutics (ELVN) and Oncolytics Biotech (ONCY) - The Globe and Mail
DBV Technologies Screens First Infant in THRIVE Peanut Patch Trial - HCPLive
DBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare Conference - markets.businessinsider.com
DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026 - The Manila Times
Peanut patch helps allergic kids with asthma and eczema in trial - Stock Titan
DBV Technologies to Present New Positive Data from VITESSE - GlobeNewswire
DBV Technologies to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference - markets.businessinsider.com
European ADRs Slip As Nokia And Sequans Lead Declines - Finimize
Dbv Technologies Adr (DBVT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Dbv Technologies Adr 주식 (DBVT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Mohideen Pharis | Chief Medical Officer |
Jan 29 '26 |
Sale |
4.86 |
534 |
2,595 |
144,995 |
| EPIC Bpifrance | Member of 10% owner group |
Dec 17 '25 |
Sale |
4.85 |
2,076,990 |
10,070,232 |
8,595,472 |
| EPIC Bpifrance | Member of 10% owner group |
Dec 18 '25 |
Sale |
4.19 |
1,292,103 |
5,413,912 |
7,303,369 |
| Mohideen Pharis | Chief Medical Officer |
Nov 20 '25 |
Sale |
2.88 |
6,496 |
18,708 |
103,153 |
| Mohideen Pharis | Chief Medical Officer |
Nov 21 '25 |
Sale |
2.77 |
1,624 |
4,498 |
101,529 |
0.00%
3.22%
자본화:
|
볼륨(24시간):